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Summary
Streptomyces sp. NTK937, producer of benzoxazole
antibiotic caboxamycin, produces in addition a
methyl ester derivative, O-methylcaboxamycin.
Caboxamycin cluster, comprising one regulatory and
nine structural genes, has been delimited, and each
gene has been individually inactivated to demon-
strate its role in the biosynthetic process. The
O-methyltransferase potentially responsible for
O-methylcaboxamycin synthesis would reside out-
side this cluster. Five of the genes, cbxR, cbxA,
cbxB, cbxD and cbxE, encoding a SARP transcrip-
tional regulator, salicylate synthase, 3-oxoacyl-ACP-
synthase, ACP and amidohydrolase, respectively,
have been found to be essential for caboxamycin
biosynthesis. The remaining ﬁve structural genes
were found to have paralogues distributed through-
out the genome, capable of partaking in the process
when their cluster homologue is inactivated. Two of
such paralogues, cbxC’ and cbxI’, coding an AMP-
dependent synthetase-ligase and an anthranilate
synthase, respectively, have been identiﬁed. How-
ever, the other three genes might simultaneously
have more than one paralogue, given that cbxF
(DAHP synthase), cbxG (2,3-dihydro-2,3-dihydroxy-
benzoate dehydrogenase) and cbxH (isochoris-
matase) have three, three and ﬁve putative
paralogue genes, respectively, of similar function
within the genome. As a result of genetic manipula-
tion, a novel benzoxazole (30-hydroxycaboxamycin)
has been identiﬁed in the salicylate synthase-deﬁ-
cient mutant strain DcbxA. 30-hydroxycaboxamycin
derives from the cross-talk between the caboxam-
ycin and enterobactin pathways.
Introduction
Streptomyces sp. NTK937, a deep-sea sediment actino-
mycete collected off the coast of the Canary Islands,
produces the benzoxazole antibiotic caboxamycin (1)
(Fig. 1) (Hohmann et al., 2009). The benzoxazole family
of compounds include members with two benzoxazole
motifs such as UK-1 (Ueki et al., 1993), AJI9561 (Sato
et al., 2001) or nataxazole (Sommer et al., 2008), and
members such as caboxamycin and A33853 (Michel
et al., 1984) with a simpler structure, bearing only one
benzoxazole motif, formed by the fusion of a 3-hydro-
xyanthranilate and a salicylate moieties or two moieties
of 3-hydroxyanthranilate respectively. Even though
caboxamycin (1) has a lower cytotoxicity than UK-1 or
nataxazole, it has shown additional antibiotic properties
against Gram-positive bacteria, as well as inhibition of
phosphodiesterases, potential targets for treating asth-
matic inﬂammation and chronic obstructive pulmonary
disease (Hohmann et al., 2009). On the other hand, the
chemically obtained caboxamycin methyl ester (2) (Fig. 1)
has been recently reported to inhibit hepatitis C virus repli-
cation (Talley et al., 2016). These activities are a small
part of the wide array of pharmacological activities shown
by benzoxazole scaffold-carrying molecules (Singh et al.,
2015). Therefore, elucidation of caboxamycin biosynthetic
cluster would be of great interest to study the many possi-
bilities benzoxazoles can offer. The knowledge gathered
by unravelling the caboxamycin pathway will open up the
opportunity to generate novel benzoxazole derivatives
with improved biological properties such as antibiotic, anti-
fungal, cytotoxic and others. This aim might be fulﬁlled
using different biotechnological approaches including
combinatorial biosynthesis and mutasynthesis.
In a previous work, we have reported the genome
sequencing and analysis of Streptomyces sp. NTK937
(Olano et al., 2014), identifying up to 35 putative gene
clusters probably involved in secondary metabolite
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production. Caboxamycin biosynthesis might be the
result of the fusion of a 3-hydroxyanthranilic acid
(3HAA) unit with a salicylic acid (SA) moiety. The most
reasonable biosynthetic origin of 3HAA might be the
same as in the calcimycin, nataxazole and A33853
biosynthesis pathways, which have been previously
reported (Wu et al., 2011; Cano-Prieto et al., 2015a; Lv
et al., 2015), that is, as a direct derivative of chorismate
instead of a catabolic by-product of tryptophan. Mean-
while, biosynthesis of SA has been described in two
possible ways, both stemming from chorismate, either
in two steps via isochorismate synthase and isochoris-
mate-pyruvate lyase (Gross and Loper, 2009), or in a
single step performed by a salicylate synthase (Kerbarh
et al., 2005). These putative biosynthetic origins of
caboxamycin can be used to identify the correct biosyn-
thesis gene cluster. Additionally, the Streptomyces sp.
NTK937 genome contains several non-ribosomal pep-
tide synthase (NRPS)-harbouring clusters (Olano et al.,
2014), one of which, based on its similarity to the
enterobactin cluster in Streptomyces sp. T€u6176 (Cano-
Prieto et al., 2015b), might be responsible for the pro-
duction of this siderophore. The presence of this cluster
in caboxamycin producer Streptomyces sp. NTK937 led
us to investigate a possible relationship between cabox-
amycin and enterobactin biosynthesis pathways through
the shikimate pathway, the source of their common pre-
cursor, chorismate. This type of metabolic relationship
was previously reported for nataxazole and enterobactin
pathways (Cano-Prieto et al., 2015b).
In this work, we report the identiﬁcation and characteri-
zation of the complete gene cluster for caboxamycin
biosynthesis in Streptomyces sp. NTK937. Individual
and independent inactivation of all the genes in the clus-
ter and the heterologous expression of the cluster led us
to propose a plausible pathway for caboxamycin biosyn-
thesis and to identify several paralogues distributed
throughout Streptomyces sp. NTK937 genome that col-
laborate in the process. Complementation of the cabox-
amycin defective mutant strains generated in this work
using orthologue genes involved in the biosynthesis of
nataxazole led to further understanding of the nataxazole
biosynthesis pathway. Furthermore, we show the pro-
duction of two caboxamycin derivatives, one derived of
an O-methyltransferase activity encoded by a gene
residing outside of the cluster, and a second one gener-
ated by cross-talk between caboxamycin and enter-
obactin biosynthesis pathways.
Results
Identiﬁcation of caboxamycin biosynthesis gene cluster
Having considered the possible biosynthetic origin of
caboxamycin as a fusion of 3HAA and SA, the
sequenced genome of Streptomyces sp. NTK937 (ac-
cession no. JJOB01000000) was scanned for putative
adequate open reading frames. For the origin of 3HAA,
the hypothesis is analogue to that of closely related ben-
zoxazole nataxazole (Cano-Prieto et al., 2015a), where it
derives from modiﬁcation of chorismate, as opposed to
catabolism of tryptophan by modiﬁcation of kynurenine
(Li et al., 2009). Four anthranilate synthase coding
genes were identiﬁed, two of which (DT87_23880 and
DT87_29875) were located next to additional genes
encoding the required enzyme activities 2,3-dihydro-2,3-
dihydroxybenzoate dehydrogenase (DT87_23870 and
DT87_28500) and isochorismatase (DT87_23875 and
DT87_29880) for the biosynthesis of 3HAA, as well as a
DAHP synthase (DT87_23865 and DT87_29890) that
would favour the biosynthesis of the chorismate precur-
sor 3-deoxy-D-arabinohept-2-ulosonate-7-phosphate
(DAHP) (Tables 1 and 2). For SA, two possible biosyn-
thetic pathways were evaluated: a direct conversion from
chorismate performed by a salicylate synthase as
described for Irp9 in yersiniabactin biosynthesis (Kerbarh
et al., 2005), a situation that has been also noted in the
cross-talk production of UK-1 by nataxazole producer
Streptomyces sp. T€u6176 (Cano-Prieto et al., 2015b); or
through a two-step process performed by isochorismate
synthase and isochorismate-pyruvate lyase, such as the
pyochelin PchA-PchB system (Gross and Loper, 2009).
Genome mining revealed only one isochorismate syn-
thase (DT87_28495, entC) (Table 2), but no presence of
a putative isochorismate-pyruvate lyase was detected.
However, two putative salicylate synthases were identi-
ﬁed. One of the salicylate synthase coding genes,
DT87_25870 (Table 2), contains a frameshift mutation
that would cause the putative protein to become non-
functional, as was demonstrated by heterologous
expression of the gene in S. albus J1074, where no SA
Fig. 1. Chemical structures of caboxamycin and caboxamycin derivatives identiﬁed in this work.
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production was observed (Supporting information,
Fig. S1). The second salicylate synthase coding gene,
DT87_23840, was shown to direct the biosynthesis of
SA when expressed in S. albus J1074 (Supporting infor-
mation, Fig. S1), and lies in close vicinity to one of the
DAHP synthase, 2,3-dihydro-2,3-dihydroxybenzoate
dehydrogenase, isochorismatase and anthranilate syn-
thase clusters (DT87_23865 to DT87_23880) previously
mentioned (Fig. 2A and Table 1). The whole set of
genes was recognized by antiSMASH analysis, which
includes the putative genes as part of a larger NRPS-
containing biosynthetic cluster. Taking in consideration
the genes located in DT87_23835 to DT87_23880
region, which encode all the activities that might be
required for the biosynthesis of caboxamycin, we pro-
pose a putative pathway for the biosynthesis of this ben-
zoxazole (Fig. 2B).
Bioinformatic analysis of the putative cluster gives
some interesting homologies with previously described
enzymes that concur with our general hypothesis, such
as the salicylate synthase CbxA being most similar to
salicylate synthases SsfH of the SF2575 (Pickens et al.,
2010) and Ccb3 of the celesticetin (Janata et al., 2015)
clusters, or the anthranilate synthase CbxI being most
similar to phenazine biosynthesis PhzE, which has actu-
ally been described as member of a very small family of
ADIC synthases (Culbertson and Toney, 2013) instead
of a true anthranilate synthase. Meanwhile, others share
very diverse homologies, such as the AMP-dependent
synthetase-ligase CbxC that shares homologies with a
series of adenylating enzymes such as EsmD2, SnbA,
MxcE and TrsI tha participate in the biosynthesis of
saphenamycin (Rui et al., 2012) pristinamycin (De
Crecy-Lagard et al., 1997), myxochelin (Gaitatzis et al.,
2001) and triostin A (Praseuth et al., 2008), respectively,
and whose only common characteristic is the adenyla-
tion of a 2-hydroxy-aromatic acid, all of them different
from salicylic acid.
Table 1. Caboxamycin biosynthesis gene cluster region in Streptomyces sp. NTK937.
Gene
Location
DT87_ Proposed function
Orthologue in
nataxazole clustera Most similar proteinb
orf-9 23 790 Acyl carrier protein – WP_043498560 (74/86) S. glaucescens
orf-8 23 795 Class III aminotransferase – WP_052413620 (81/88) S. glaucescens
orf-7 23 800 AMP-dependent synthetase-ligase – WP_051422268 (99/99) Streptomyces sp.
DpondAA-B6
orf-6 23 805 Phenylalanine-speciﬁc permease – WP_051422266 (99/99) Streptomyces sp.
DpondAA-B6
orf-5 23 810 TetR-family transcriptional regulator – WP_043498549 (78/86) S. glaucescens
orf-4 23 815 EmrB/QacA drug resistance transporter – WP_052414047 (78/86) S. glaucescens
orf-3 23 820 Leucine-carboxyl methyltransferase – WP_043483949 (60/68) S. olivaceus
orf-2 23 825 AsnC-family transcriptional regulator – WP_052410747 (76/86) S. olivaceus
orf-1 23 830 EmrB/QacA drug resistance transporter – WP_037748866 (99/99) Streptomyces sp.
DpondAA-B6
cbxR 23 835 SARP-family transcriptional regulator natR4 (51.7/39.3) WP_052410743 (99/99) S. olivaceus
cbxA 23 840 Salicylate synthase CF54_20720c(60.7/49.3) WP_028441039 (99/100) Streptomyces sp.
DpondAA-B6
cbxB 23 845 3-oxoacyl-ACP synthase III natS (66.8/54.8) WP_031037807 (62/76) S. olivaceus
cbxC 23 850 AMP-dependent synthetase-ligase natL1 (70.6/60.8) WP_038519516 (65/74) Amycolatopsis japonica
natL2 (48.2/22.0)
cbxD 23 855 Acyl carrier protein natAC1 (60.3/46.5) SBU95399
Streptomyces sp. OspMP-M45natAC2 (49.6/22.6)
cbxE 23 860 Amidohydrolase natAM (67.4/55.6) WP_031508998 (62/75) S. megasporus
cbxF 23 865 Class II DAHP synthase natAL (60.3/48.0) SCD89909 (99/99) Streptomyces sp. PalvLS-984
cbxG 23 870 2,3-dihydro-2,3- dihydroxybenzoate
dehydrogenase
natDB (70.9/62.0) SCD8992 (98/98)
Streptomyces sp. PalvLS-984
cbxH 23 875 Isochorismatase natIS (69.5/63.4) EsmA4 (72/78)
S. antibioticus
cbxI 23 880 Anthranilate synthase natAN (65.9/54.5) WP_051422252 (99/99) Streptomyces sp.
DpondAA-B6
orf+1 23 885 ATP-binding ABC transporter – WP_030870615 S. violaceoruber (89/94)
orf+2 23 890 Molybdate ABC transporter – WP_028441031 (100/100) Streptomyces sp.
DpondAA-B6
orf+3 23 895 Molybdate binding protein – WP_028441030 (99/98) Streptomyces sp.
DpondAA-B6
orf+4 23 900 MerR-family transcriptional regulator – WP_003992129 (91/96) S. viridochromogenes
orf+5 23 910 Cobalamin-independent
methionine synthase
– WP_028441028 (99/99) Streptomyces sp.
DpondAA-B6
a. % level of identity at gene and deduced protein in parenthesis.
b.% level of identity and similarity in parenthesis.
c. Involved in UK-1 biosynthesis in nataxazole producer Streptomyces sp. T€u6176.
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Genetic characterization of the caboxamycin
biosynthesis gene cluster in Streptomyces sp. NTK937
The involvement of the genes located in DT87_23835 to
DT87_23880 region in caboxamycin biosynthesis was ini-
tially proven through inactivation of the salicylate synthase
coding gene DT87_23840 (cbxA), which led to mutant
strain DcbxA. Analysis of products accumulated by mutant
DcbxA in comparison with the wild-type strain (Fig. 3A)
showed the disappearance of two peaks, one correspond-
ing to caboxamycin (1) and a second one (2) with charac-
teristic benzoxazole absorption spectrum, UPLC retention
time of 6.0 min and mass of m/z 270 [M+H]+. Structural
elucidation of compound 2 showed it corresponds to ben-
zoxazole O-methylcaboxamycin (Fig. 1), compound previ-
ously generated only by total synthesis (Talley et al.,
2016). In addition to the disappearance of caboxamycin
(1) and O-methylcaboxamycin (2), mutant strain DcbxA
accumulated a novel compound (3) with an absorption
spectrum reminiscent of benzoxazoles, UPLC retention
time of 4.3 min and mass of m/z 272 [M+H]+. Structural
elucidation of compound 3 showed it corresponds to 30-
hydroxycaboxamycin (Fig. 1), which includes a 2,3-dihy-
droxybenzoate moiety, probably originated from the enter-
obactin biosynthesis pathway, cluster where the
aforementioned isochorismate synthase DT87_28495
(entC) lies (Table 2). The existence of a cross-talk
between caboxamycin and enterobactin biosynthesis
pathways that led to the production of 30-hydroxycaboxa-
mycin (3) in mutant strain DcbxA was demonstrated
through inactivation of the enterobactin isochorismate
synthase coding gene entC both in Streptomyces sp.
NTK937 and in DcbxA strain, leading to mutant strains
DentC and DcbxA/DentC respectively. Analysis of prod-
ucts accumulated by mutant DentC showed the normal
production of caboxamycin (1) and O-methylcaboxamycin
(2) while the double mutant strain DcbxA/DentC was
unable to produce any benzoxazole, including 30-hydroxy-
caboxamycin (3) (Fig. 3A).
According to our biosynthetic hypothesis, the caboxam-
ycin biosynthesis gene cluster might require only the nine
distinct open reading frames lying between salicylate syn-
thase and anthranilate synthase (DT87_23840 to
DT87_23880, cbxA to cbxI), and an opposite direction
gene upstream of salicylate synthase cbxA that codiﬁes a
SARP-like regulator (DT87_23835, cbxR). Indeed, the
inactivation of cbxR leading to mutant strain DcbxR abol-
ishes benzoxazole production (Fig. 3B), result that justi-
ﬁes its possible role as a positive transcriptional regulator.
In addition to cbxR and cbxA, each gene in the cabox-
amycin biosynthesis cluster was independently inacti-
vated leading to the corresponding mutant strains
(Fig. 3C). As it was observed in the aforementioned
mutant strains DcbxA and DcbxR, production of 1 and 2
was suppressed in DcbxB, DcbxD and DcbxE mutant
strains. The remaining mutant strains, DcbxC, DcbxF,
DcbxG, DcbxH and DcbxI, showed normal production of
caboxamycin (1) with minor alterations in the production
of O-methylcaboxamycin (2). Even the simultaneous
deletion of all four genes involved in the biosynthesis of
precursor 3HAA (cbxF, cbxG, cbxH and cbxI), leading to
mutant strain Dcbx[FGHI], could only reduce the produc-
tion of caboxamycin by approximately two-thirds
(Fig. 3C). These results are in apparent contradiction
with our initial pathway proposal, as all the genes pre-
sent in the cluster were considered essential in
Table 2. Caboxamycin biosynthesis paralogue genes located in Streptomyces sp. NTK937.
Gene Location DT87_ Proposed function Most similar proteina
cbxA’ 25 870 Salicylate synthase WP_028443031 (97/97)
Streptomyces sp. DpondAA-B6
cbxC’ 23 710 AMP-dependent synthetase-ligase WP_028441054 (99/99)
Streptomyces sp. DpondAA-B6
cbxI’ 29 875 Anthranilate synthase WP_051422472 (99/99)
Streptomyces sp. DpondAA-B6
cbxH’ 29 880 Isochorismatase GAT84341 (79/88)
Streptomyces sp. F-3
cbxG’ 29 885 2,3-dihydro-2,3- dihydroxybenzoate dehydrogenase WP_028443631 (98/99)
Streptomyces sp. DpondAA-B6
cbxF’ 29 890 Class II DAHP synthase WP_028443630 (99/99)
Streptomyces sp. DpondAA-B6
cbxF’’ 05 590 Class II DAHP synthase WP_031081129 (97/99)
Streptomyces sp. NRRL WC-3549
entA 28 500 2,3-dihydro-2,3- dihydroxybenzoate dehydrogenase;
enterobactin biosynthesis gene cluster
WP_028440609 (98/97) Streptomyces sp. DpondAA-B6
entB 28 485 Isochorismatase; enterobactin biosynthesis gene cluster WP_014049800 (92/91) Streptomyces sp. SirexAA-E
entC 28 495 Isochorismate synthase; enterobactin biosynthesis gene
cluster
WP_028440610 (99/99) Streptomyces sp. DpondAA-B6
a. % identity/similarity in parenthesis
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Fig. 2. (A) Genetic organization of caboxamycin biosynthesis gene cluster in Streptomyces sp. NTK937. (B) Proposed pathway for caboxam-
ycin biosynthesis. 3HAA, 3-hydroxyanthranilate; ADIC, 2-amino-2-deoxyisochorismate; DAHP, 3-deoxy-D-arabinohept-2-ulosonate-7-phosphate;
DHHA, Trans-2,3-dihydro-3-hydroxyanthranilate; E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate.
Fig. 3. (A) UPLC analysis of Streptomyces sp. NTK937 wild-type (WT) and mutant strains DcbxA, DentC and DcbxA/DentC. (B) UPLC analysis
mutant strain DcbxR. (C) UPLC analysis of mutant strains carrying individual inactivation of each structural gene of the caboxamycin biosynthe-
sis cluster. Extracts were obtained from cultures grown in R5A medium for 7 days. UPLC chromatograms were analysed at 330 nm. Labelled
peaks correspond: caboxamycin A (1), O-methylcaboxamycin (2), 30-hydroxycaboxamycin (3).
ª 2017 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 10, 873–885
Caboxamycin biosynthesis pathway 877
caboxamycin biosynthesis, and point to additional genes
in the genome of Streptomyces sp. NTK937 being
involved in caboxamycin biosynthesis (see below).
On the other hand, simultaneous inactivation by gene
replacement of several contiguous genes both upstream
of cbxR (orf-3, orf-2 and orf-1) and downstream of cbxI
(orf+1, orf+2 and orf+3) showed no effect on caboxam-
ycin production, and neither did the individual inactiva-
tion of more distant putative regulators of the TetR and
MerR families of transcriptional regulators (orf-5 and
orf+4) (Supporting information, Fig. S2), thus delimiting
the borders of the caboxamycin biosynthesis gene clus-
ter from cbxR to cbxI.
Heterologous expression of the caboxamycin
biosynthesis gene cluster
The limits of the cluster were further established through
heterologous expression of the cluster using a TAR-clon-
ing approach. The nine structural genes transcribed in the
same direction, cbxABCDEFGHI, were expressed in
Streptomyces lividans JT46 host using pCABTAR and
leading to a noticeable production of caboxamycin (1).
This production was increased by simultaneous overex-
pression of the SARP regulator coding gene cbxR (pT-
cbxR), not originally included in pCABTAR (Fig. 4). Addi-
tionally, the simultaneous expression of cbxABCDEFGHI
and cbxR resulted in a remarkable accumulation of the
precursor SA (4) together with the ﬁnal product caboxam-
ycin (Fig. 4). In none of these heterologous expression
approaches, the production of O-methylcaboxamycin (2)
was detected, due to the absence of a speciﬁc O-methyl-
transferase among the structural genes of caboxamycin
biosynthesis harboured in pCABTAR.
Genetic characterization of the caboxamycin biosynthesis
gene cluster paralogues in Streptomyces sp. NTK937
We attempted to clarify the question of the presence of
additional genes in the genome of Streptomyces sp.
NTK937 that complement the loss activity of
caboxamycin biosynthesis genes cbxCFGHI when any
of these was inactivated. As it has been mentioned
above, several paralogues of identical putative function
as those present within the caboxamycin biosynthesis
cluster have been identiﬁed throughout the genome of
Streptomyces sp. NTK937, and they could act as back-
up copies supplying the lost function in the genes
replacement mutants. In the case of cbxC, multiple pos-
sibilities for AMP-dependent synthetase-ligase coding
genes exist within the genome. One of such genes is
DT87_23710 (cbxC’), located only 24 orfs upstream from
the beginning of the caboxamycin cluster, whose
deduced product presents an amino acid sequence iden-
tity of 51% to CbxC. The double mutant strain DcbxC/C’
showed no production of caboxamycin nor O-methylca-
boxamycin, while the mutant strain DcbxC’ still produced
normal amounts of both compounds (Fig. 5A). These
results clearly demonstrate the role of cbxC’ as a back-
up system for caboxamycin biosynthesis. Yet another
AMP-dependent synthetase-ligase coding gene, orf-7
(DT87_23800), exists in between cbxC and cbxC’, only
7 orfs upstream from cbxR (Fig. 2A). However, the inac-
tivation of orf-7 independently (Dorf-7) or in a double
mutant (DcbxC/-7) had no effect over the biosynthesis of
benzoxazoles (Fig. 5A), therefore excluding orf-7 from
any role in caboxamycin biosynthesis. This is coincident
with the bioinformatic analysis of orf-7 deduced product,
which shows higher identity between CbxC and CbxC’
than between CbxC and Orf-7 (16%).
After failing to cancel out caboxamycin production in
the DcbxF mutant, DAHP synthase paralogues, cbxF,
cbxF’ (DT87_29890) and cbxF’’ (DT87_05590), were
analysed by sequence homology, together with their
orthologues from nataxazol producer Streptomyces sp.
T€u6176, natAL and CF54_24340 (located outside natax-
azole biosynthetic cluster). Protein sequence alignments
show that CbxF presents higher identity to CbxF’ (62%)
and NatAL (46%) than to CbxF’’ (42%). Besides, CbxF’’
is 91% identical to CF54_24340. Given that DAHP syn-
thase is an enzyme required for primary metabolism as
the ﬁrst dedicated step in the chorismate pathway,
CF54_24340 and cbxF’’ might fulﬁl this role in their
respective strains, which leaves out cbxF’ as the putative
paralogue of cbxF for caboxamycin biosynthesis. Never-
theless, a double mutant strain DcbxF/F’ is still able to
synthesize 1 and 2, and so is the alternative DcbxF/F’’
(Supporting information, Fig. S12A). The generation of a
triple DcbxF/F’/F’’ is unfeasible, given that at least one
DAHP synthase is required to maintain the vital shiki-
mate pathway. We sought to repress the action of
whichever aldolase is responsible for primary metabo-
lism by supplementing culture media with each individual
aromatic aminoacid (Light and Anderson, 2013), but
already in the wild-type strain is shown that all three
Fig. 4. UPLC analysis showing production of caboxamycin (1) and
salicylic acid (4) in cultures of S. lividans JT46 carrying pCAP01,
pCABTAR or pCABTAR + pT-cbxR, grown in R5A medium for
7 days. UPLC chromatograms were analysed at 330 nm.
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aldolases present in the genome are repressed by a
tryptophan feedback, annulling the biosynthesis of ben-
zoxazoles (Supporting information, Fig. S12B). There-
fore, it is impossible to ascertain whether all three
aldolases are simultaneously partaking in benzoxazole
biosynthesis, or whether the third one only comes into
action when the other two are absent.
In the case of 2,3-dihydro-2,3-dihydroxybenzoate
dehydrogenase (cbxG) and isochorismatase (cbxH),
three and ﬁve paralogues exist, respectively, for each of
them within the genome, with the cbxG paralogue lying
always in close vicinity to a cbxH-like gene. After individ-
ual DcbxG and DcbxH mutants failed to suppress cabox-
amycin production, we took into consideration the other
two genomic loci where they are closely related, one of
which is next to the aforementioned cbxF’ and the other
one being within the enterobactin cluster (entA and
entB), that has already been proven to participate in a
cross-talk with the caboxamycin pathway for the biosyn-
thesis of 30-hydroxycaboxamycin in DcbxA mutant strain.
The generation of double mutants in any of these genes
in tandem with their caboxamycin biosynthesis gene par-
alogue failed to abrogate caboxamycin biosynthesis, but
the simultaneous replacement of all three genes in
DcbxG/[FGHI]’/entA and DcbxH/[FGHI]’/entB mutants
succeeded in abolishing caboxamycin and O-methylca-
boxamycin biosynthesis (Fig. 5B and C).
Finally, anthranilate synthase (cbxI) counts up to four
putative paralogues within the Streptomyces sp. NTK937
genome. After showing that a mutant strain with all four
3HAA-related genes removed (Dcbx[FGHI]) was still able
to synthesize caboxamycin (Fig. 3C), although at lower
production levels, we succeeded in making a non-produ-
cing mutant by deleting in tandem the previously men-
tioned locus cbx[FGHI]’. Given that there are four gene
products in this group, cbxF’, cbxG’, cbxH’ and cbxI’ that
Fig. 5. UPLC analysis of Streptomyces sp. NTK937 wild-type (WT) and different mutant strains. (A) AMP-dependent synthetase-ligase-deﬁcient
mutant strains. (B) 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase-deﬁcient mutant strains. (C) Isochorismatase-deﬁcient mutant strains. (D)
Anthranilate synthase-deﬁcient mutant strains. Extracts were obtained from cultures grown in R5A medium for 7 days. UPLC chromatograms
were analysed at 330 nm. Labelled peaks correspond to caboxamycin A (1), O-methylcaboxamycin (2) and 30-hydroxycaboxamycin (3).
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could potentially partake in caboxamycin biosynthesis, it
became necessary to replace these genes (cbx[FGHI]’)
in each corresponding individual caboxamycin biosynthe-
sis gene-deleted mutant (DcbxF, DcbxG, DcbxH, DcbxI).
Only the DcbxI/[FGHI]’ mutant resulted in a non-produ-
cing phenotype (Fig. 5D), given that the others are still
supported, respectively, by the actions of cbxF’’, entA
and entB, therefore indicating that the sole real par-
alogue of cbxI would be cbxI’ (DT87_29875).
Cross-complementation of caboxamycin non-producer
mutants using nataxazole biosynthesis genes from
Streptomyces sp T€u6176
The reintroduction of each replaced gene succeeded in
restoring the biosynthesis of caboxamycin (1) and/or O-
methylcaboxamycin (2) in all non-producing mutants,
whether simple, double or triple (Supporting information,
Fig. S3A to S11). An exception is the salicylate synthase
DT87_25870 (cbxA’), which, as expected due to the
presence of a frameshift mutation, did not restore cabox-
amycin production (Supporting information, Fig. S4), and
its heterologous expression in S. albus did not induce
SA accumulation, unlike its homologues (Supporting
information, Fig. S1).
Meanwhile, expression of nataxazole biosynthesis clus-
ter orthologue genes in these same mutant strains was
successful in most cases, although often with a lower pro-
duction (Supporting information, Fig. S3A, S5 to S7 and
S9 to S11), with notable exception of natAM which failed
to complement the DcbxE mutant strains, in which, on the
other hand, the biosynthesis of caboxamycin was only
restored to minimal levels by complementation with the
original cbxE (Supporting information, Fig. S8). In the case
of CF54_20720, which encodes a salicylate synthase
responsible for UK-1 biosynthesis in Streptomyces sp.
T€u6176, the complementation of DcbxA is partial, leading
to simultaneous production of 1, 2 and 3 (Supporting infor-
mation, Fig. S4), the latter being the natural cross-talk pro-
duct of the DcbxA mutant strain. Furthermore, the fact that
natL1/natAC1 can, respectively, restore 1 and 2 produc-
tion while natL2/natAC2 cannot (Supporting information,
Fig. S4 and S5) gives further proof on their performing
order in nataxazole biosynthesis pathway, making natL1/-
natAC1 likely responsible for the 6MSA-3HAA fusion, as
they are capable of performing this fusion with the closely
related SA, while natL2/natAC2 would be in charge of the
3HAA-3HAA benzoxazole scaffold formation. Coinciden-
tally, the natL2-overexpressing DcbxC/DcbxC’ mutant
strain shows the production of 30-hydroxy-caboxamycin
(3) (Supporting information, Fig. S6) which further indi-
cates NatL2 preference for binding 3HAA-like compounds
such as 2,3-dihydroxybenzoate, which only differs in
switching the amino group for a hydroxyl group.
Ectopic expression of the cbxR regulator in Strepto-
myces sp. NTK937 wild-type strain resulted in yields up
to 40 times higher for 1 and 2 (Supporting information,
Fig. S3B), while its nataxazole orthologue, natR4,
although capable of complementing the DcbxR mutant
(Supporting information, Fig. S3A), has barely any effect
on the wild-type strain caboxamycin production levels.
The nataxazole biosynthesis cluster repressors, belong-
ing to the TetR-family of transcriptional regulators, natR2
and natR3, were likewise ectopically expressed in Strep-
tomyces sp. NTK937, but they failed to exert any
decrease in caboxamycin production, in comparison with
their role in nataxazole biosynthesis (Supporting informa-
tion, Fig. S3B).
Biological activity of caboxamycin and derived
benzoxazoles
The antibiotic activities of caboxamycin (1), O-methylca-
boxamycin (2) and 30-hydroxycaboxamycin (3) were
tested by antibiotic disc diffusion assays against S. albus
J1074, E. coli, Staphylococcus aureus, Micrococcus
luteus and the yeast Candida albicans. None of them
showed activity against bacteria, but growth of C. albi-
cans was inhibited by 2.5 lg of caboxamycin or 10 lg of
30-hydroxycaboxamycin. These results, in particular the
absence of antibiotic activity against Gram-positive bac-
teria, are puzzling considering that previous reports
showed caboxamycin being active against Bacillus sub-
tilis, Staphylococcus lentus and Staphylococcus epider-
midis (Hohmann et al., 2009). However, after running
the biological activity tests several times, we can con-
clude that S. albus, S. aureus and M. luteus are clearly
not affected, in our experimental conditions, by cabox-
amycin or its two derivatives.
Cytotoxicity of 1 – 3 was tested against a selection of
tumoral cell lines: HT29 (colon), A549 (lung), MDA-MB-
231 (breast), AGS (gastric) and A2780 (ovarian), as well
as a mouse non-malignant cell line NIH/3T3 as control
test. Only 2 showed activity at IC50 concentrations of
3.7 lM (HT29), 2.7 lM (A549), 6.1 lM (MDA-MB-231),
5 lM (AGS), 4.93 lM (A2780) and 5.14 lM (NIH/3T3),
while 1 and 3 showed no activity up to 10 lM. In con-
trast to the relative activities of AJ9561 and nataxazole,
where the presence of a methyl ester group in nataxa-
zole renders this compound less active than AJ9561
(Cano-Prieto et al., 2015a), the methyl ester group in O-
methylcaboxamycin confers to this compound a higher
cytotoxic activity than that of caboxamycin.
Discussion
The Streptomyces sp. NTK937 caboxamycin biosyn-
thetic cluster was identiﬁed in silico and conﬁrmed by
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both gene inactivation and heterologous expression in
S. lividans JT46. It consists of ten genes, nine of which
encode structural enzymes responsible for biosynthesis,
plus one SARP-like transcriptional regulator. These
genes might be organized in as many as four distinct
operons: one for the regulator, and the others organized
as cbxABCDE, cbxFG and cbxHI, given the fact of their
overlapping start and stop codons. The caboxamycin
pathway involves the synthesis of 3-hydroxyanthranilic
and salicylic acid from chorismate, their activation and
attachment into an ACP and their subsequent condensa-
tion involving the participation of amidohydrolase CbxE.
The O-methyltransferase required for O-methylcaboxa-
mycin biosynthesis is not located in the vicinity of the
cluster and thus has yet to be identiﬁed. This enzymatic
activity, in contrast to what has been shown for nataxa-
zole biosynthesis in Streptomyces sp. T€u6176 (Cano-
Prieto et al., 2015a), does not appear to constitute a
resistance mechanism as caboxamycin is not active
against Streptomyces spp.
While a structural gene lying outside the cluster is
uncommon for actinomycetes, several cases have been
reported (Karki et al., 2010; Huang et al., 2015), includ-
ing the closely related nataxazole cluster, where an
undetermined O-methyltransferase outside the cluster is
responsible for the conversion of AJI9561 into nataxa-
zole (Cano-Prieto et al., 2015a). Even less common is
the presence of several paralogues codifying genes that
can act as backups for the cluster structural genes
(Tahlan et al., 2004; Engelhardt et al., 2010). In the
case of AMP-dependent synthetase-ligase coding cbxC’
and the paralogue set cbx(FGHI)’, they could be consid-
ered as isoenzymes, as they are not ascribed to any
other biosynthetic pathway. On the other hand, in the
case of 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase entA and isochorismatase entB, they have been
demonstrated to exhibit a certain degree of catalytic
promiscuity, given that they accept 3-hydroxyanthrani-
late precursors as well as their expected 2,3-dihydroxy-
benzoate precursors, as they can back up the loss of
cbxG and cbxH respectively. Besides, isochorismate
synthase EntC show a cross-talk interaction with the
caboxamycin biosynthesis pathway when salicylate
synthase coding cbxA is removed, leading to the gener-
ation of a novel caboxamycin derivative: 30-hydroxyca-
boxamycin.
Finally, most of the caboxamycin biosynthesis genes,
including the regulatory gene cbxR, can be substituted
by their corresponding orthologue from the nataxazole
biosynthesis gene cluster. In the case of ACP coding
cbxD, it can be only substituted by natAC1 but not by
natAC2; and for the AMP-dependent synthetase-ligase
coding cbxC, the correct substitute is natAL1 but not
natAL2. The exception to this general rule is the
aminohydrolase coding cbxE that cannot be backed up
by natAM. This result indicates the essential role of this
activity in the biosynthesis of benzoxazoles. Amidohydro-
lases CbxE and NatAM might participate by themselves
or in combination with other enzymatic activities in the
choice of precursors to be incorporated into the ﬁnal
benzoxazole moiety during the biosynthesis of caboxam-
ycin and nataxazole.
Conclusions
Streptomyces sp. NTK937 presents a versatile metabo-
lism for the biosynthesis of benzoxazole compounds of
the caboxamycin type. This includes the presence of
several paralogues of the caboxamycin biosynthesis
structural genes and others that can interact by cross-
talk with the caboxamycin pathway. This metabolic net-
work allows the production of at least two caboxamycin
derivatives: O-methylcaboxamycin and 30-hydroxycabox-
amycin. The metabolic versatility of this pathway might
allow the generation of novel caboxamycin derivatives
using different biotechnological approaches involving
genetic engineering such as combinatorial biosynthesis
and mutasynthesis.
Experimental procedures
Strains, culture conditions and plasmids
Streptomyces sp. NTK937 (Hohmann et al., 2009), pro-
ducer of caboxamycin; Streptomyces sp. T€u6176 (Som-
mer et al., 2008), producer of nataxazole; Streptomyces
albus J1074 (Chater and Wilde, 1976) and Streptomyces
lividans JT46 (Tsai and Chen, 1987) were used as
heterologous hosts for gene and cluster expression,
respectively; E. coli DH10B (Invitrogen, Pfullingen, Ger-
many) and E. coli ET12567 (pUB307) (Kieser et al.,
2000) were used for subcloning and intergeneric conju-
gation respectively. Yeast strain Saccharomyces cere-
visiae VL6-48 (MAT a, his3-D200, trp1-D1, ura3-52, lys2,
ade2-101, met14, psi+ cir0) was used for transformation-
associated recombination (TAR) cloning. For Strepto-
myces species, tryptone soy broth (TSB) was used for
growth, MA for conjugation and sporulation and R5A for
secondary metabolite production (Fernandez et al.,
1998). E. coli culture media LB and 2xTY were used as
described (Green and Sambrook, 2012). Yeast transfor-
mants were selected on YNB-trp medium, and yeast
colonies were cultured overnight in YPD medium (Cano-
Prieto et al., 2015a).
Where plasmid-bearing or mutant strains were used,
media were supplemented with their due antibiotic: ampi-
cillin (100 lg ml1), apramycin (100 lg ml1 for E. coli,
25 lg ml1 for Streptomyces), thiostrepton (50 lg ml1),
hygromycin (50 lg ml1), kanamycin (25 lg ml1),
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tetracycline (10 lg ml1), chloramphenicol (25 lg ml1)
and/or nalidixic acid (50 lg ml1).
Two main plasmids were used: pEM4T (Menendez
et al., 2006) for gene expression and pEFBAoriT (Horna
et al., 2011) for gene replacement. pCR-Blunt (Invitro-
gen) was used for routine PCR product cloning for veriﬁ-
cation. Yeast/E. coli shuttle-actinobacterial chromosome
integrative vector pCAP01 (Yamanaka et al., 2014) was
used both for the TAR-cloning process and as a source
of the kanamycin resistance aph(3)II gene. pSETeTc
(Cano-Prieto et al., 2015a) was used as source of the
thiostrepton resistance tsr gene, and pLHyg (Olano
et al., 2004) as the source of the hygromycin resistance
hyg gene.
DNA manipulation
Database searching and sequence analysis were carried
out with the bioinformatics tools antiSMASH (Blin et al.,
2013; Weber et al., 2015) and BLAST (Altschul et al.,
1997). DNA manipulations were performed according to
standard procedures for E. coli (Green and Sambrook,
2012) and Streptomyces (Kieser et al., 2000). PCR
ampliﬁcations were carried out with Herculase II Fusion
DNA Polymerase (Agilent Technologies, Madrid, Spain)
following an optimized standard PCR procedure on a
SureCycler 8800 thermocycler (Agilent Technologies):
initial denaturation at 99.9°C for 2 min, 30 cycles com-
prised of 99.9°C denaturation for 10 s, 65°C annealing
for 20 s and 72°C elongation at 30 s per kb of DNA to
be ampliﬁed, plus an extra ﬁnal cycle of 72°C for 3 min.
Products of the expected size were cloned into pCR-
Blunt for sequence veriﬁcation. All oligonucleotides used
in this work are shown in Tables S1–S3 (Supporting
information). PCR products were subsequently cloned
into appropriate vectors using the selected restriction
sites incorporated in the oligonucleotides.
Construction of plasmids
Gene replacement pEFBAoriT plasmids were con-
structed by ligating the corresponding ~2 kb up- and
downstream fragments ﬂanking the apramycin resistance
gene aac(3)IV in the plasmid, followed by cloning of the
tsr gene, taking advantage of a XbaI restriction site
located immediately before oriT. These constructions
were introduced into Streptomyces sp. NTK937 through
intergeneric conjugation from E. coli ET12567(pUB307)
and then screened simultaneously for apramycin resis-
tance and thiostrepton sensitivity, indication of a suc-
cessful double cross-over event. In pEFBAoriT plasmids
for the creation of double mutant strains, an intermediate
step is required, where aac(3)IV is excised and replaced
by tsr using the NheI additional sites included in the
corresponding oligonucleotides, followed by introduction
of hyg as a SpeI-NheI fragment in the same XbaI site as
previously described. Double mutants were sought in the
same fashion as single ones and likewise screened for
thiostrepton resistance and hygromycin sensitivity. The
plasmids for triple mutant generation were built similarly,
excising aac(3)IV in favour of hyg, then using aph(3)II as
the second marker and screening colonies for hygromy-
cin resistance and kanamycin sensitivity. All mutants
were further conﬁrmed by PCR ampliﬁcation of the
replaced gene, given the differing sizes of the antibiotic
resistance gene versus the original orf. In cases where
the difference in size was < 100 bp (cbxC, cbxE, cbxF’),
additional differential enzymatic digestion was performed
(Supporting information, Fig. S13).
Gene expression plasmids derived of pEM4T were
constructed by appropriate digestion and directed liga-
tion using the available BamHI and EcoRI sites. Where
cohesive ends were not available, fragments and vector
were previously made blunt-ended according to the pro-
tocol for Platinum Pfx DNA polymerase (Thermo Fisher
Scientiﬁc, Barcelona, Spain). After intergeneric conjuga-
tion, colonies were screened for thiostrepton resistance.
Overexpression plasmids derived of pEM4HT (pHT-) and
pEM4KT (pKT-), used for complementation assays (Sup-
porting information, Table S2) in double and triple mutant
strains, were created by a posteriori opening of the ﬁnal
construction at the sole EcoRV site in the middle of the
tsr gene, and blunt-ended ligation of the hyg or aph(3)II
gene, respectively, and then introduced as well by conju-
gation. Overexpression plasmids containing genes from
the nataxazole biosynthesis cluster were readily used
when available (Cano-Prieto et al., 2015a), or generated
as described here for the genes not available (Support-
ing information, Table S2).
Heterologous expression of the entire cluster was gen-
erated on the trifunctional pCAP01 vector according to
protocol (Yamanaka et al., 2014). Oligonucleotide pairs
CABTAR/AB and CABTAR/CD were used to generate
the capturing arms and then ligated into pCAP01 to gen-
erate capture plasmid pCAB. BamHI-linearized pCAB
and MfeI-PstI-digested (restriction sites loosely ﬂanking
the caboxamycin cluster region) Streptomyces sp.
NTK937 genomic DNA were co-transformed into Sac-
charomyces cerevisiae VL6-48 following the LiAc/PEG/
ssDNA method (Gietz and Schiestl, 2007). Yeast trans-
formants were selected on YNB-trp medium and
screened by PCR for the presence of caboxamycin
biosynthetic genes. Positive colonies were grown on
YPD medium overnight and subjected to glass beads
DNA extraction (Hoffman and Winston, 1987). The
resulting construction, pCABTAR, was then introduced
into Streptomyces lividans JT46 by protoplast transfor-
mation (Kieser et al., 2000).
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Analysis of metabolites by UPLC and HPLC-MS
Cultures of selected strains or mutants were extracted
with ethyl acetate containing 1% formic acid (to enhance
the extraction of compounds containing ionizing groups)
and analysed by reverse phase chromatography with an
Acquity UPLC instrument ﬁtted with a BEH C18 column
(1.7 lm, 2.1 9 100 mm; Waters, Barcelona, Spain),
using acetonitrile (AcN) and aqueous 0.1% triﬂuoroacetic
acid (TFA) as eluents. The program uses an isocratic
hold of 10% AcN for 1 min, followed by a linear gradient
up to 100% AcN over 7 min, at a ﬂow rate of
0.5 ml min1 and a column temperature of 35°C.
For HPLC-MS analysis, an Alliance chromatographic
system coupled to a ZQ4000 mass spectrometer and a
SunFire C18 column (3.5 lm, 2.1 9 150 mm; Waters)
was used. Solvents were the same as above, and elu-
tion was performed with an initial isocratic hold with 10%
AcN during 4 min followed by a linear gradient of AcN
(10% to 88%) over 30 min, all at 0.25 ml min1. MS
analysis was carried out by positive mode electrospray
ionization (ESI), with a capillary voltage of 3 kV and a
cone voltage of 20 V. Spectral identiﬁcation and charac-
terization of peaks were performed in both cases by
photodiode array detection at 330 nm, using Empower
software (Waters) to extract bidimensional chro-
matograms at different wavelengths, depending on the
spectral characteristics of the desired compound.
Isolation and structural characterization of compounds
Liquid production cultures were generally incubated at
30°C and 250 rpm for 7 days, and then, 1 ml of samples
from each of the ﬂasks was extracted with an equal volume
of acidiﬁed ethyl acetate. Solid production cultures were
carried out using 25-well plates with 1.5 ml solid R5A med-
ium each and inoculated with a sterile cotton swab, then
incubated at 30°C for 7 days and extracted with an equal
volume of acidiﬁed ethyl acetate. Both types of samples
were subsequently vacuum-dried and redissolved in 50:50
DMSO:MeOH before chromatographic analysis.
Products 1 – 3 were isolated from 5 9 400 ml (in 2 l
ﬂasks) cultures whose supernatants were ﬁrst ﬁltered,
then concentrated on a C18 cartridge (10 g; Waters) and
subsequently fractioned on a 0.1%TFA–MeOH gradient.
Fractions were submitted to UPLC analysis, and the
fractions containing desired compounds were dried in
vacuo, resuspended in 50:50 DMSO:MeOH and pro-
cessed on a preparative HPLC SunFire C18 column
(10 lm, 10 9 250 mm; Waters) using experimentally
determined isocratic mixtures of 0.05%TFA with either
AcN or MeOH at 5 ml min1. The purity of the isolated
peaks was determined by HPLC-MS before structural
elucidation. The isolated compounds were then dried in
vacuo, resuspended in 50:50 tert-butanol:water and lyo-
philized. Structural elucidation was carried out by a com-
bination of 1H, 13C, COSY and HSQC experiments using
DMSO-d6 as solvent (Supporting information, Fig. S14 to
S16 and Tables S4 and S5).
Bioactivity assays
The antibiotic activities of 1 – 3 were analysed with an
antibiotic disc diffusion assay against S. albus J1074,
E. coli, Staphylococcus aureus and Micrococcus luteus.
The antifungal activity was tested against Candida albi-
cans. In all cases, 1, 2.5, 5, 10 and 20 lg of each com-
pound was used. Plates were incubated overnight at
37°C for E. coli, S. aureus and M. luteus and at 30°C for
S. albus J1074 and C. albicans.
Cytotoxic activity of compounds 1 – 3 was tested against
the following human tumour cell lines: colon adenocarci-
noma (HT29), non-small cell lung cancer (A549), breast
adenocarcinoma (MDA-MB-231), gastric carcinoma (AGS)
and ovarian carcinoma (A2780). Mouse embryonic ﬁbrob-
last cell line NIH/3T3 was used as control to evaluate cyto-
toxicity against non-malignant cells. Cells were previously
grown for a week on DMEM-10% FBS medium, then ali-
quoted to 5000 cells per well in 96-well plates using the
Cell counting kit-8-(96992) (Sigma-Aldrich, Barcelona,
Spain) and grown for an extra 24 h. Compounds were dis-
solved in DMSO, keeping in mind that ﬁnal concentration
of DMSO in the assays should be kept at 0.1%. After the
incubation, 10 ll of compound (in diverse concentrations)
was added to each well and incubated for another 48 h.
Lastly, 10 ll of CCK-8 reagent (Sigma-Aldrich) was added,
left to develop for 2 h in the incubator and measured at
450 nm using an Elisa Bio-tek ELx 800 (BioTek, Winooski,
VT, United States).
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